ABSTRACT
A study was conducted in Brazil to evaluate the efficacy of danofloxacin 18% (Advocin 180TM Pfizer Inc.), in the treatment of infectious diseases in cattle including respiratory disease, enteritis, metritis or omphalitis. The clinical cases were scored as: 0 - normal; 1 - mild; 2 - moderate; 3 - severe. Animals with scores of 0 or 3 were not included in the study. On Day 0, animals with scores 1 and 2 received a SC injection of danofloxacin 18% (6 mg/kg). On Day 2, the animals were clinically scored as above and the cured animals (score 0) were removed from the study. Non-responder animals (same score or higher than Day 0 score) received a second injection of danofloxacin 18%. On Day 4, the animals were re-examined and the study finished. Before treatment on Day 0, fecal samples and nasal, vaginal and navel swabs, as appropriate to the disease, were collected for bacterial isolation and bacterial sensitivity testing using "Sensidisc" containing 5 mcg of danofloxacin. A total of 1,019 cattle were treated from which, 966 (94.8%) responded to the treatment, and 857 (84.1%) were cured: 52.4% with a single dose and 31.7% with two doses. The cure rates in each clinical category were: Respiratory disease = 79.8%; enteritis = 92.6%; metritis = 76.5% and omphalitis = 88.0%. A total of 805 bacterial isolates were obtained, of which 70.4% were sensitive, 20.0% partially sensitive and, 9.6% were resistant to danofloxacin. Danofloxacin 18% was safe and very effective in the treatment of naturally occurring infectious diseases in cattle.
KEY WORDS:
Danofloxacin 18%; Advocin 180TM; cattle; infectious diseases; treatment; efficacy.